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Purpose of the study
PAF, a potent inflammatory mediator, seems to play a role
in the pathogenesis of several AIDS manifestations. PAF-
antagonists have been studied in this context with prom-
ising results. We have previously described the in vitro
interaction between HAART and PAF-induced platelet
aggregation, as well as between HAART and the specific
activities of the basic PAF metabolic enzymes.
Methods
In order to examine the in vivo interactions between PAF
and HAART, we studied the effect of antiretroviral treat-
ment on PAF-induced platelet aggregation and on the spe-
cific activities of the basic PAF metabolic enzymes from
blood samples of HIV-patients.
Summary of results
15 naive, male HIV-infected patients were started on
HAART. 8/15 received tenofovir-DF/emtricitabine/efa-
virenz (group A) and 7/15 abacavir/lamivudine/efavirenz
(group B), based on our previous in vitro results showing
the former having one of the most potent activities against
PAF and the latter one of the weaker ones. The in vivo
effects of HAART on the specific activities of the basic PAF
metabolic enzymes (PAF-CPT, Lyso-PAF-AT and PAF-AH)
of plasma, washed human leukocytes (WHLs), and
washed human platelets (WHPs) at baseline and after 6
months on HAART were studied. 8/15 patients (four in
each group), who completed 6 months on HAART were
included in our final analysis. In group A, a significant
reduction (63%) of the specific activity of PAF-CPT of
WHLs was observed after 6 months while the specific
activities of plasma-PAF-AH, Lyso-PAF-AT of WHLs, as
well as both PAF-CPT and Lyso-PAF-AT of WHPs,
remained relatively stable. In contrast, in group B, PAF-
CPT of WHLs, plasma-PAF-AH, as well as both PAF-CPT
and Lyso-PAF-AT of WHPs, remained relatively stable
while the specific activity of Lyso-PAF-AT of WHLs was
doubled.
Conclusion
Our preliminary in vivo results confirm the previous in
vitro ones: group A's regimen retained its ability to reduce
PAF production while group B's regimen seems to
enhance it. Further studies are needed to confirm these
results and to unveil any possible clinical implications of
anti-PAF activity of HAART.
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